Therefore, it can be confirmed that BCR: ABL is a strong inducer of HO-1 expression and one can expect that targeting HO-1 in BCR::ABL+ CML cells may be more beneficial than in BCR: ABL− CML cells. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.